Stempeutics successfully completes Phase 2 clinical trial to treat critical limb ischemia

Stempeutics has successfully completed a Phase 2 clinical trial that aims to treat patients suffering from Buerger’s disease with a stem cell-based product.

Go to the profile of Elena Conroy
Sep 09, 2015
0
0

Stempeutics Research (Bangalore, India) has successfully completed Phase 2 clinical trial of Stempeucel, a novel stem cell-based medicinal product designed to treat critical limb ischemia caused by Buerger’s disease, a rare illness with an unmet medical need both in India and globally.

Buerger's disease is a rare and severe disease affecting the blood vessels of the limbs. It is characterized by inflammation and occlusion of the vessels of extremities resulting in reduced blood flow to these areas. This leads to severe rest pain and ulcers or necrosis, which finally leads to amputation of the limbs. Stempeucel treatment is designed to enhance the body's limited capability to restore blood flow in ischemic tissue by reducing inflammation and improving blood flow to the affected limb.

The Phase 2 trial conducted by Stempeutics is the largest ever Phase 2 trial in no-option patients with Buerger’s disease in the world. In the trial, Stempeucel demonstrated statistically significant results in ulcer healing, rest pain reduction, increased Ankle Brachial Pressure Index (indicator of increased blood flow due to neo-angiogenesis) and general improvement in quality of life.

Stempeucel has been given the Advanced Therapeutic Medicinal Product designation and the disease has been granted the Orphan Drug designation by the EMA.

“The company has spent the last nine years developing innovative stem cell products that could provide a cure for chronic and degenerative diseases. Stempeucel is developed from allogeneic pooled mesenchymal stromal cells extracted from the bone marrow of healthy, adult voluntary donors,” explained BN Manohar, CEO of Stempeutics. “The drug works by increasing blood flow which is the root cause of diseases and just does not give symptomative relief, thus proving to be much more effective agent of treatment. Stempeutics’s proprietary pooling technology allows an efficient manufacturing process with minimum wastage of resources in order to provide the product at an affordable cost to patients.”

Stempeucel has a strong patent protection with 18 patent applications filed across the globe. So far, the core patent has been granted in US, Australia, New Zealand, Singapore, South Africa, China and Japan.

“Stem cell research is continually advancing knowledge on how an organism develops from a single cell and how healthy cells are derived from precursor cells to replace damaged tissue. All this knowledge and data is then used in developing stem cell treatments for diseases that do not have a cure yet, with an aim to replace/regenerate damaged cells with healthy cells,” concluded BN Manohar.

Source: Pharmabiz.com: http://pharmabiz.com/ArticleDetails.aspx?aid=90413&sid=1&utm_source=feedburner&utm_medium=twitter&utm_campaign=Feed%3A+PharmabizNews+%28Pharmabiz+Top+News%29

Go to the profile of Elena Conroy

Elena Conroy

Contributor, Future Science Group

If you have any interest in submitting to the journal Regenerative Medicine or have any queries, please don't hesitate to contact my colleague Adam, Commissioning Editor of the journal https://www.regmednet.com/users/19471-adam-price-evans.

No comments yet.